RMD vs NVCR vs MDT vs SYK vs ZBH

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate ResMed Inc. (RMD) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Stryker Corporation at 35. 0x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: RMD returned +293. 8% versus ZBH's -17. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, ResMed Inc. (RMD) carries a lower debt/equity ratio of 14% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: ResMed Inc. grew EPS 37. 4% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, RMD leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zimmer Biomet Holdings, Inc. (ZBH) trades at 9. 8x forward P/E versus 19. 6x for Stryker Corporation — 9. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, MDT (3.

6% yield), ZBH (1. 1% yield), SYK (1. 1% yield), RMD (1. 0% yield) pay a dividend. NVCR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RMD is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; SYK is a mid-cap quality compounder stock; ZBH is a mid-cap quality compounder stock. RMD, MDT, SYK, ZBH pay a dividend while NVCR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.